Safety and Efficacy of Autologous Induced Neural Stem Cell-derived Dopaminergic Precursor Cells in the Treatment of Parkinson's Disease
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This is a phase I, interventional, single arm, open-label, clinical study to evaluate the safety and efficacy of the striatal transplantation of autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 30
Maximum Age: 85
Healthy Volunteers: f
View:
• Ages between 30 and 85 years, males or females; Diagnosed to be Parkinson's disease patients according to MDS Parkinson's disease diagnostic criteria; Disease history over 3 years; Hoehn and Yahr Stage less than or equal to 4 during the medication on time; Responsive to levodopa treatment (Maximum rate of improvement in MDS-UPDRS, part 3, is over 30%).
Locations
Other Locations
China
Xuanwu Hospital Capital Medical University
RECRUITING
Beijing
Contact Information
Primary
Zhiguo Chen, Ph.D.
chenzhiguo@gmail.com
+86-10-83198889
Backup
Jinghong Ma, M.D.
jinghongma@163.com
+86-10-83198677
Time Frame
Start Date: 2023-06-13
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 10
Treatments
Experimental: Autologous induced neural stem cell-derived DA precursor cells
The patients will receive transplantation of autologous induced neural stem cell-derived DA precursor cells.
Related Therapeutic Areas
Sponsors
Leads: Xuanwu Hospital, Beijing